Beyond the Guidelines: Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis

被引:2
|
作者
Tompkins, Madeline G. [1 ]
Pettit, Rebecca [1 ]
机构
[1] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN USA
关键词
cystic fibrosis; corticosteroids; pulmonary; antifungals; biopharmaceutics; ANTI-IGE ANTIBODY; OMALIZUMAB TREATMENT; THERAPY; POSACONAZOLE; PATIENT; ABPA; BENRALIZUMAB; AMPHOTERICIN; MANAGEMENT; CHILDREN;
D O I
10.1177/10600280211022065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To review the available literature addressing alternative allergic bronchopulmonary aspergillosis (ABPA) treatment options for patients with cystic fibrosis (CF). Data Sources: A literature search of PubMed was performed (January 2002 to April 2021) using the following search terms: allergic bronchopulmonary aspergillosis, aspergillus-related lung disease, cystic fibrosis. Manufacturer prescribing information, clinical practice guidelines, and data from ClinicalTrials.gov were incorporated in the reviewed data. Study Selection and Data Extraction: Relevant English-language studies or those conducted in humans were considered for inclusion. Data Synthesis: Available literature for alternative ABPA treatments in CF is lacking randomized controlled trials, but there is considerable support in case reports and case series describing the benefits in pediatric and adult patients. Recent literature has begun to explore the place in therapy for novel, corticosteroid-sparing treatment approaches. The alternative therapies summarized in this review all resulted in clinical improvement and subsequent discontinuation or dose reductions of oral corticosteroids, with minimal reported adverse drug effects. Relevance to Patient Care and Clinical Practice: Although corticosteroids are the cornerstone of ABPA management, the toxicities can be significant limitations in an already high-risk patient population. Patients may fail or become intolerant to guideline-recommended therapies and require alternative treatment approaches. Conclusions: Alternative treatment modalities for ABPA in patients with CF, including azole antifungals, pulsed intravenous glucocorticoids, omalizumab, mepolizumab, and inhaled amphotericin, appear to be efficacious and well tolerated. Pharmacological properties including route of administration, storage and stability, beyond use dating, and adverse effects of the various treatment modalities must be considered when selecting a practical care plan for patients.
引用
收藏
页码:181 / 192
页数:12
相关论文
共 50 条
  • [1] Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosis
    Epps, Quovadis J.
    Epps, Kevin L.
    Zobell, Jeffery T.
    Young, David C.
    PEDIATRIC PULMONOLOGY, 2020, 55 (12) : 3541 - 3572
  • [2] Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis
    Emiralioglu, Nagehan
    Dogru, Deniz
    Tugcu, Gokcen Dilsa
    Yalcin, Ebru
    Kiper, Nural
    Ozcelik, Ugur
    ANNALS OF PHARMACOTHERAPY, 2016, 50 (03) : 188 - 193
  • [3] Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients
    Nove-Josserand, Raphaele
    Grard, Soazic
    Auzou, Lila
    Reix, Philippe
    Murris-Espin, Marlene
    Bremont, Francois
    Mammar, Benyebka
    Mely, Laurent
    Hubert, Dominique
    Durieu, Isabelle
    Burgel, Pierre-Regis
    PEDIATRIC PULMONOLOGY, 2017, 52 (02) : 190 - 197
  • [4] Allergic bronchopulmonary aspergillosis in cystic fibrosis
    Steiss, J. O.
    Lindemann, H.
    ALLERGOLOGIE, 2013, 36 (06) : 275 - 281
  • [5] Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
    Lehmann, Sylvia
    Pfannenstiel, Claus
    Friedrichs, Frank
    Kroeger, Kristina
    Wagner, Norbert
    Tenbrock, Klaus
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2014, 8 (05) : 141 - 149
  • [6] Allergic bronchopulmonary aspergillosis and cystic fibrosis
    Levy, MB
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2003, 8 : S579 - S583
  • [7] Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review
    Manti, Sara
    Giallongo, Alessandro
    Parisi, Giuseppe Fabio
    Papale, Maria
    Mule, Enza
    Aloisio, Donatella
    Rotolo, Novella
    Leonardi, Salvatore
    EUROPEAN RESPIRATORY REVIEW, 2022, 31 (165):
  • [8] Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
    Ashkenazi, Moshe
    Sity, Saray
    Sarouk, Ifat
    El Bar Aluma, Bat
    Dagan, Adi
    Bezalel, Yael
    Bentur, Lea
    De Boeck, Kris
    Efrati, Ori
    JOURNAL OF ASTHMA AND ALLERGY, 2018, 11 : 101 - 107
  • [9] Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis
    Zicari, A. M.
    Celani, C.
    De Castro, G.
    De Biase, R. Valerio
    Duse, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (13) : 1839 - 1841
  • [10] Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis
    Thronicke, Anja
    Heger, Nikola
    Antweiler, Elisabeth
    Krannich, Alexander
    Roehmel, Jobst
    Brandt, Claudia
    Staab, Doris
    Tintelnot, Kathrin
    Schwarz, Carsten
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2016, 27 (06) : 597 - 603